AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Nov 9, 2026, 8:01 AM ET Xencor Presents Initial Plamotamab Data in Rheumatoid Arthritis at ACR Convergence 2026 and Updates Progress in First-in-Human Study of XmAb657 Headline · Source: company release
NASDAQ: $XNCRBiotech · Antibody medicinesEarly clinical and contingent-revenue risk

XNCR Stock Hub: Xencor News, XmAb819 and XmAb942

Xencor reported $116.520M of Q3 revenue and $39.436M of net income, including settlement and milestone effects. Cash and debt securities totaled $555.690M at September 30. XmAb819 has a proposed Phase 3 dose, while autoimmune programs advance after early human observations. The wholly owned pipeline remains investigational. Q3 2026 Form 10-Q · November 4 Q3 results and development outlook · November 4, 2026 Plamotamab and XmAb657 clinical update · November 9, 2026

Last updated: November 12, 2026Market data: November 11, 2026 regular closeFinancial period: September 30, 2026Currency: USD
Research Library · Biotech
Xencor: XmAb819, Autoimmune Programs and Partner Royalties
Engineered antibodies, early clinical cohorts and contingent revenue · November 12, 2026
Get the report (PDF)
Next catalyst · company analysis window · blinded interim
Around year-end 2026 · XENITH-UC blinded interim analysis

The Phase 2b XmAb942 study has a planned blinded interim analysis around year-end. This is distinct from the primary week-12 clinical-remission analysis expected in H2 2027 and does not constitute a promised public efficacy readout. Q3 results and development outlook · November 4, 2026

Another near-term target: one further XmAb657 healthy-participant single-dose cohort by year-end; patient MAD enrollment is planned for Q1 2027. Plamotamab and initial XmAb657 observations were already announced November 9. Plamotamab and XmAb657 clinical update · November 9, 2026
XNCR daily price chart
Daily chart · Finviz (affiliate link on click). Explore XNCR on JC Just Charts.

XNCR stock data: financial position and capital

Reference close
$39.97
November 11 regular session
Basic equity value
$2.999B
Calculated using October 30 shares
Cash + debt securities
$555.690M
September 30 · excludes Zenas equity
Q3 revenue
$116.520M
Collaboration, milestone and royalty revenue
Operating cash used
$120.644M
Nine months ended September 30
Common shares
75.040M
October 30 cover count
Royalty-sale obligations
$95.060M
September 30 · accounting financing liability
Year-end cash guidance
$480M–$500M
Cash, equivalents and debt securities · forecast

September resources: cash $59.622M, current debt securities $318.487M and long-term debt securities $177.581M. Zenas equity $26.970M is separate. Royalty-sale obligations include the $23.133M current and $71.927M non-current portions; these are not additive to the total. Q3 2026 Form 10-Q · November 4

XNCR stock: clinical progress and uneven revenue quality

Q3 revenue included $77.4M of Alexion settlement consideration recognized for post-June U.S. royalty rights and $29M of milestones. The $105M settlement ends future U.S. Ultomiris royalties after full payment; ex-U.S. rights remain. Quarterly profit is not a measure of recurring product earnings. Q3 2026 Form 10-Q · November 4

▲ The constructive case

Partner milestones, retained royalties and resources support a broad internal pipeline. XmAb819 proposed dose selection and early autoimmune observations provide specific development paths for further testing. Q3 results and development outlook · November 4, 2026 Plamotamab and XmAb657 clinical update · November 9, 2026

▼ The cautious case

Early cohorts are small and nonrandomized, while XmAb819 safety includes substantial severe related events. Partner revenue is uneven, royalty obligations affect cash retention and internal development consumes capital. XmAb819 dose-selection results · October 25, 2026 Q3 2026 Form 10-Q · November 4

Latest XNCR news

Nov 9, 2026

Xencor presents initial plamotamab rheumatoid arthritis data; updates XmAb657 first-in-human study

Xencor presented initial plamotamab data in rheumatoid arthritis at ACR Convergence 2026. The company also updated progress in the first-in-human study of XmAb657.

Company release · Business Wire

XNCR stock catalysts: XENITH-UC, XmAb819 and autoimmune studies

November 9 plamotamab and XmAb657 observations are already reported. Obexelimab has already been submitted and accepted for review. Estimated registry completion dates are distinct from company disclosure and enrollment windows. Plamotamab and XmAb657 clinical update · November 9, 2026 Zenas Q3 2026 Form 10-Q · obexelimab review

XmAb819 dose selection and safety

The 400 mcg/kg IV efficacy-evaluable group comprised 11 patients: five confirmed partial responses, or 45.5% confirmed ORR, with an additional unconfirmed response. Xencor selected this as its proposed Phase 3 dose. Q3 results and development outlook · November 4, 2026 XmAb819 dose-selection results · October 25, 2026

Across 68 expansion-cohort patients at the September 1 cutoff, grade 3-or-higher related events occurred in 72.1%; grade 3-or-higher CRS and discontinuations due to related events each occurred in 5.9%. Dose-level efficacy and pooled safety use different denominators. XmAb819 dose-selection results · October 25, 2026

The expansion analysis excluded one participant with approximately tenfold unintended exposure who developed grade 4 CRS, fully recovered and discontinued treatment. Xencor reported suspected dose-preparation errors in three of 69 expansion patients before a new formulation was introduced. XmAb819 dose-selection results · October 25, 2026

XmAb942, plamotamab and XmAb657

XENITH-UC tests XmAb942 in ulcerative colitis with week-12 clinical remission as the primary endpoint. XmAb412 is a separate TL1A × IL23p19 bispecific in healthy-participant development. Q3 results and development outlook · November 4, 2026

November 9 plamotamab data covered nine rheumatoid-arthritis patients across four cohorts; the higher-dose groups had preliminary week-12 improvements. One grade 1 CRS event and one serious renal event judged unrelated to treatment were reported. XmAb657 observations covered 30 healthy participants; patient enrollment is planned for Q1 2027. Plamotamab and XmAb657 clinical update · November 9, 2026

Merlintrader Health Score · XNCR

3.55out of 5
Financial position4.0

September 30 cash and debt securities totaled $555.690M; nine-month operating cash use was $120.644M. Management forecasts year-end resources of $480M–$500M and funding into 2029 under its operating plan, which includes potential milestone receipts. Q3 2026 Form 10-Q · November 4 Q3 results and development outlook · November 4, 2026

Catalysts3.5

A blinded XENITH-UC interim analysis is planned around year-end 2026, with the primary endpoint analysis in H2 2027. XmAb819 data and FDA discussions are targeted for H1 2027; the approval pathway is not agreed. Q3 results and development outlook · November 4, 2026

Dilution3.0

September capital included 14,637,750 options and 2,369,594 RSUs. Historical pre-funded warrants add residual exposure, and the $200M ATM remained unused; future financing can expand the share count. Q3 2026 Form 10-Q · November 4 2025 Form 10-K · February 25, 2026

Trading liquidity3.5

XNCR common stock trades on Nasdaq with an active daily price history. Clinical announcements and large price moves can change spreads and execution conditions. Q3 2026 Form 10-Q · November 4

Execution3.5

XmAb819 reached proposed dose selection and the autoimmune portfolio produced early human observations. Q3 profit included settlement and milestone effects, while XmAb819 expansion cohorts had substantial grade 3-or-higher related adverse events. Q3 2026 Form 10-Q · November 4 XmAb819 dose-selection results · October 25, 2026 Plamotamab and XmAb657 clinical update · November 9, 2026

Weighted calculation: 4.0 × 30% + 3.5 × 30% + 3.0 × 20% + 3.5 × 10% + 3.5 × 10% = 3.55 out of 5. Editorial assessment as of November 12, 2026. Weights: financial position 30%, catalysts 30%, dilution 20%, trading liquidity 10%, execution 10%. Not an investment recommendation or probability of clinical success.

XNCR red flags

XNCR Stock FAQ: Xencor Questions Answered

When is the next XNCR stock catalyst?

As of November 12, 2026, Xencor plans a blinded XENITH-UC interim analysis around year-end 2026. The primary week-12 clinical-remission analysis is forecast for H2 2027. The blinded interim is distinct from a promised public efficacy readout; another near-term target is an additional XmAb657 healthy-participant cohort. Q3 results and development outlook · November 4, 2026 Plamotamab and XmAb657 clinical update · November 9, 2026

Are Xencor XmAb819 and XmAb942 FDA approved?

No, as of November 12, 2026, Xencor’s XmAb819 and XmAb942 remain investigational. Planned FDA discussions for XmAb819 in H1 2027 do not establish an agreed accelerated-approval pathway. Partner Zenas has a separate accepted obexelimab BLA with a May 27, 2027 target date. Q3 results and development outlook · November 4, 2026 Zenas Q3 2026 Form 10-Q · obexelimab review

How much cash does Xencor have?

At September 30, 2026, Xencor held $555.690 million of cash and marketable debt securities, excluding restricted balances and its Zenas equity holding. Management forecasts $480 million to $500 million at year-end and funding into 2029 under its current operating plan, including potential milestone receipts. Q3 2026 Form 10-Q · November 4 Q3 results and development outlook · November 4, 2026

Can XNCR stock face share dilution?

At September 30, 2026, Xencor had 14,637,750 options and 2,369,594 RSUs outstanding. Historical pre-funded warrants add residual exposure, and the $200 million ATM had not issued shares. Outstanding instruments, plan capacity and future financing are separate from already issued common shares. Q3 2026 Form 10-Q · November 4 2025 Form 10-K · February 25, 2026

When did Xencor report Q3 earnings?

Xencor reported Q3 2026 results on November 4, 2026: revenue was $116.520 million and net income was $39.436 million. Revenue included Alexion settlement recognition and partner milestones. Nine-month operating activities used $120.644 million, so quarterly profit does not establish a recurring cash-generating run rate. Q3 2026 Form 10-Q · November 4 Q3 results and development outlook · November 4, 2026

What does Xencor do?

As of November 12, 2026, Xencor develops engineered antibodies for cancer and autoimmune diseases. It advances its own clinical programs and licenses protein-engineering technologies to partners. Revenue comes from collaborations, milestones and royalties, while wholly owned drug candidates remain in clinical development. Q3 2026 Form 10-Q · November 4 Q3 results and development outlook · November 4, 2026

What were Xencor XmAb819 Phase 1 results?

As reported in October 2026, the 400 mcg/kg IV efficacy-evaluable group had five confirmed partial responses among 11 patients, or 45.5% confirmed ORR. Across the separate 68-patient expansion safety population, 72.1% had grade 3-or-higher related events. These small early data require further evaluation. XmAb819 dose-selection results · October 25, 2026

What did Xencor announce about plamotamab and XmAb657?

On November 9, 2026, Xencor reported initial plamotamab rheumatoid-arthritis observations in nine patients and XmAb657 findings in 30 healthy participants. Higher-dose plamotamab groups showed preliminary week-12 improvements. XmAb657 patient enrollment is planned for Q1 2027; healthy-participant B-cell reductions do not establish patient efficacy. Plamotamab and XmAb657 clinical update · November 9, 2026

Primary sources

Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent journalism and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $XNCR or any other security.

Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases, ClinicalTrials.gov and market data, and are stated with their reference dates. Data can change without notice. Readers should verify every figure against the primary source before acting on it.

Clinical-stage biotechnology companies carry high execution, regulatory and financing risk. Trials fail, endpoints miss, enrollment slips, regulators ask for more data or decline to file an application, and companies that spend ahead of revenue raise equity at whatever price the market will bear. Every reader is responsible for their own decisions and should consult a licensed financial adviser where appropriate. Investors may lose part or all of their capital.

Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.

Trending now

Bright illustration of blood cells, medicines and molecular structures for hereditary angioedema research.
BioCryst $BCRX $IONS $TAK $NTLA: HAE Treatment Choices
Colorful minerals and processing infrastructure illustrating rare-earth co-product economics.
Ramaco $METC $AREC $NB $UUUU: Rare Earth Economics
Colorful semiconductor memory stack and inspection equipment illustrating the AI memory supply chain.
Micron $MU, $RMBS, $AMKR, $CAMT: AI Memory Economics
LNG carrier, onshore facility and floating liquefaction vessel in a sunlit coastal scene.
Cheniere $LNG $VG $NEXT $GLNG: Four LNG Business Models